Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM

Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the DexCom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241217145216/en/

Alberta residents living with type 1 or type 2 diabetes who meet the eligibility criteria are now covered for Dexcom G7 (Photo: Business Wire)

Alberta residents living with type 1 or type 2 diabetes who are enrolled in a government-sponsored health benefit plan^† and meet the eligibility criteria* below may now receive coverage for Dexcom G7:

• Under 18 years of age: requiring the ongoing use of any insulin OR insulin pump therapy.
• 18 years of age and older: requiring the ongoing use of insulin pump therapy, OR a basal and bolus insulin, OR a premixed insulin.

"Canadians living with any type of diabetes understand the challenges that come with management of the condition. Dexcom G7 has been designed to make daily management easier and to help improve users' day-to-day lives – whether they’re a recently diagnosed adolescent or an adult who’s lived with the condition for decades,” said André Côté, Vice President and General Manager of Dexcom Canada. "We’re thrilled that the government of Alberta recognizes this and is introducing public coverage for eligible residents that includes both adults and children living with type 1 or type 2 diabetes on intensive insulin therapy.”

Dexcom G7 offers a better way to help users gain greater control of their glucose levels and is clinically proven to lower A1C for people living with type 1 diabetes and type 2 diabetes.^1-5 Features like its quick sensor warm-up time, a predictive Urgent Low Soon alert, and wide range of compatible digital health apps differentiate it amongst other available CGM systems in Canada, providing users with a simple, accurate⁶ and effective way to manage their diabetes day-to-day.

"The importance and value of continuous glucose monitoring (CGM) for people living with diabetes requiring insulin treatment is underscored by Canadian and international clinical practice guidelines," said Dr. Peter Senior, Endocrinologist and Director of the Alberta Diabetes Institute. "As a diabetes specialist working with patients, I have seen the benefits of CGM and the challenges faced by those who couldn’t afford it. Ensuring equitable access to CGM technology is a significant and important step forward for diabetes care in Alberta.”

Across Canada, coverage for Dexcom’s leading CGM technology has grown significantly over the last few years. This announcement brings Alberta on par with British Columbia, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and Yukon in terms of making diabetes technology like Dexcom CGM available to a broader group of those who can benefit from it.

Albertans on any type of insulin who have private insurance or are covered by the Non-Insured Health Benefits (NIHB) federal program have access to Dexcom G7 through those plans.^‡.

To learn more about Dexcom G7 and details about public or private insurance plan coverage, please visit https://www.dexcom.com/en-CA/coverage.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

_______________________________________

1 Beck RW, et al. JAMA. 2017;317(4):371-378.
2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
3 Martens T, et al. JAMA. 2021;325(22):2262-2272.
4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.
5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
6 Dexcom, data on file, 2024.

* For detailed coverage criteria, please visit https://www.dexcom.com/en-ca/coverage/alberta-health-provincial-cgm-coverage.
† To view a list of eligible government-sponsored health benefit plans, please visit https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=eef94732-04fd-42e1-8e66-68cfae3b60cb&id=0000111639&intchg_grp_nbr=1&detailId=12573683.
‡ Eligibility and coverage vary by policy, plan, and payor.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241217145216/en/